Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aldosterone to renin ratio

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Aldosterone to renin ratio. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-000051-10 Sponsor Protocol Number: A091200 Start Date*: 2008-05-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: 11C metomidate PET scanning for Conn's syndrome
    Medical condition: Primary hyperaldosteronism - Conn's syndrome and bilateral adrenal hyperplasia. Imaging of adrenal lesions using 11C-metomidate PET. Pre-suppression with dexamethasone and/or fludrocortisone to opt...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017464-17 Sponsor Protocol Number: ID_2802 Start Date*: 2010-04-15
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: Arterial Hypertension in patients with elevated aldosterone to renin ratio but negative confirmatory test for Primary Aldosteronism: comparison between anti-hypertensive efficacy of potassium canre...
    Medical condition: Arterial hypertension associated with elevated ARR
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005681-13 Sponsor Protocol Number: CLCI699A2206 Start Date*: 2008-03-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldo...
    Medical condition: hypertension artérielle par hyperaldostéronisme primaire
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039834 Secondary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-005030-38 Sponsor Protocol Number: PAT-CR-302 Start Date*: 2019-08-10
    Sponsor Name:Vifor Pharma, Inc.
    Full Title: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone Syst...
    Medical condition: Management of hyperkalemia due to renin-angiotension-aldosterone system medications in patients treated for heart failure.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10005725 Blood potassium increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed) NL (Completed) ES (Ongoing) HU (Completed) DE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001595-15 Sponsor Protocol Number: 270389-010520 Start Date*: 2020-06-23
    Sponsor Name:Henrik Birn
    Full Title: The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease
    Medical condition: Chronic kidney disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10020647 Hyperkalemia LLT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000649-30 Sponsor Protocol Number: P150905 Start Date*: 2016-09-29
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Impact of the administration of Fludrocortisone the fluid and electrolyte balance in great premature. Pilot study.
    Medical condition: Great prematurity
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004868 10053593 Premature baby 26 to 32 weeks LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002587-24 Sponsor Protocol Number: CMD_ALISKIREN Start Date*: 2011-10-20
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Effects of Aliskiren on microcirculation dysfunction in patients affected by hypertension
    Medical condition: dysfunction of coronary microcirculation in arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10010164 Hypertension complications HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005345-36 Sponsor Protocol Number: D5610C00001 Start Date*: 2014-05-13
    Sponsor Name:Ardelyx, Inc.
    Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete...
    Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000919-85 Sponsor Protocol Number: DP13C201 Start Date*: 2020-05-14
    Sponsor Name:DAMIAN Pharma AG
    Full Title: DP13 – A Phase II Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period
    Medical condition: Primary Aldosteronism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10001656 Aldosteronism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003577-26 Sponsor Protocol Number: U1111-1131-5236 Start Date*: 2012-10-24
    Sponsor Name:Aarhus University Hospital
    Full Title: Liraglutide Kidney: A randomised, double-blinded, cross-over study investigating the short-term impact of liraglutide on kidney function in diabetic patients
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002570-27 Sponsor Protocol Number: 69TER/2020 Start Date*: 2021-05-27
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: A Randomized Clinical Trial of Nafamostat: A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor for the Treatment of Covid-19
    Medical condition: Covid-19 (Coronavirus disease 2019) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001324-18 Sponsor Protocol Number: 202100178 Start Date*: 2021-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients with elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
    Medical condition: Patients with elevated Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    27.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    27.0 10027433 - Metabolism and nutrition disorders 10016807 Fluid retention PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002263-54 Sponsor Protocol Number: D7551C00001 Start Date*: 2021-03-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease
    Medical condition: Proteinuric Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002878-50 Sponsor Protocol Number: NN9535-4321 Start Date*: 2019-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) SK (Completed) BG (Completed) DE (Completed) ES (Ongoing) FR (Completed) PL (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001579-35 Sponsor Protocol Number: KBP5074-2-001 Start Date*: 2019-08-07
    Sponsor Name:KBP BioSciences Co., Ltd.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disea...
    Medical condition: Moderate to Severe Chronic Kidney Disease and uncontrolled hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:10:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA